ADCT-402-311-DLBCL
Phase III
OPEN TO ACCRUAL
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
ADICET-ADI-001-BCELL
Phase I
OPEN TO ACCRUAL
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-Engineered Allogeneic Gamma-Delta T Cells in Adults with Refractory B-Cell Malignancies
ADICET-ADI-001-LTFU
Phase N/A
OPEN TO ACCRUAL
Long-Term Follow-Up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta CAR T Cell Investigational Products
ALLOGENE-ALLO-501A-201
Phase I/II
OPEN TO ACCRUAL
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
C4THERAPEUTICS-CFT7455-1101
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
CIBMTR-10-CBA
Phase N/A
OPEN TO ACCRUAL
A Multicenter Access And Distribution Protocol For Unlicensed Cryopreserved Cord Blood Units (CBUs) For Transplantation In Pediatric And Adult Patients With Hematologic Malignancies And Other Indications
ECOG-EA4151
Phase III
OPEN TO ACCRUAL
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
IIT-ABEDIN-PTCY-RUX-GVHD
Phase II
OPEN TO ACCRUAL
A Phase II Trial of De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
IIT-HAMADANI-FLU-MEL-TBI
Phase II
OPEN TO ACCRUAL
A Phase II, Open-Label Study of Propylene Glycol-Free Melphalan for Injection (EVOMELA®) in Combination with Fludarabine and Total-Body, Irradiation-Based, Reduced-Intensity Conditioning for Haploidentical Transplantation
LOXO-BTK-20019
Phase III
OPEN TO ACCRUAL
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
MERCK-MK2140-004-DLBCL
Phase II
OPEN TO ACCRUAL
A Phase 2 Open-Label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)
MILTENYI-MB-CART2019-1-DLBCL
Phase II
OPEN TO ACCRUAL
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
NURIX-NX-5948-301
Phase I
OPEN TO ACCRUAL
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
TENEOBIO-TENEOTWO-TNB486-001
Phase I
OPEN TO ACCRUAL
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
WON-SHAH-UW18131-SPLIT-RCHOP
Phase II
OPEN TO ACCRUAL
A Phase II Study of Split-Dose R-CHOP in Older Adults with Diffuse Large B-Cell Lymphoma